Innoviva: Up as FDA expands inhaler approval for use in asthma patients

Innoviva

10/09/2020 11:33

** Biopharmaceutical co's shares  INVA.O  rise 10.92% to $13
in premarket trade
    ** Co on Wednesday after market hours said the U.S. FDA had
approved its and partner GlaxoSmithKline's  GSK.L  Trelegy
Ellipta inhaler to treat asthma patients aged 18 years and older
 urn:newsml:reuters.com:*:nBw6Tz2WJa
    ** The approval adds to the current license for use of the
inhaler in patients with chronic obstructive pulmonary disease
(COPD)  
    ** The treatment is a combination of three molecules
delivered at once through the inhaler in a once-daily dose
    ** FDA approval makes Trelegy Ellipta the first single
inhaler triple therapy approved for both asthma and COPD    
    ** As of last close, INVA stock is down 17% YTD


 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))